BRAF and non-small cell lung carcinoma: BRAF mutations, mostly non-V600E, account for 1–4% of NS-NSCLC [57] and lead to the activation of the MAPK pathway downstream of EGFR and RAS, and this kinase can be targeted by the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametimib [58,59].